Moderna Inc. on May 4 forecast higher vaccine sales for the second half of 2022 than in the first six months of the year, as the company expects the virus that causes COVID-19 to follow a more seasonal pattern requiring booster shots in the fall.
AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.
Sanofi reported a series of first-quarter 2022 wins, driven mostly by the success of consumer healthcare (CHC) and the company’s blockbuster Dupixent.
Merck announced the company’s Q1 2022 results, reporting year-over-year revenue growth of 50 percent from continuing operations, with worldwide sales increasing to $15.9 billion. As anticipated, Merck’s COVID-19 antiviral treatment Lagevrio (molnupiravir) played a role in the company’s robust sales.
Eli Lilly had a lucrative first-quarter 2022, with revenue growth rising 15 percent driven by sales of the company’s diabetes drug Trulicity and its COVID-19 antibodies.
Johnson & Johnson rescinded the company’s forecast for sales of its COVID-19 vaccine, as hesitancy in low income countries has led to a glut of supply of a shot once hoped to be the inoculation of choice for the developing world.
The U.S. Food and Drug Administration approved CTI BioPharma Corp.’s drug for treating adult patients with a type of bone marrow cancer who also have low blood platelet count.
AbbVie reported the company’s fourth-quarter 2021 and full-year financial results on Feb. 2, with worldwide net reviews up 7.4% to $14.89 billion for the quarter. Total revenues for 2021 were $56 billion. The company’s anchor product remains Humira, which will begin to lose exclusivity in 2023.
As a class of drugs to treat high cholesterol, PCSK9 inhibitors have had trouble gaining tracking in the marketplace.
A report by Evaluate Pharma estimates prescription drug sales will hit $1.18 trillion by 2024, driven by cell and gene therapies.